RekrutujeFaza III
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received…
Miasta: Biała Podlaska, Białystok, Brzozów, Gdańsk i 5 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza I
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Miasta: Gdańsk, Katowice, Kraków, SkórzewoWiek: od 65 latSponsor: Janssen Cilag International
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza II
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Miasta: Gdańsk, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza IV
HOPE Against Cancer Recurrence in HCC
Miasta: Gdańsk, WarszawaWiek: od 18 latSponsor: Philipp Dutkowski
RekrutujeFaza II/III
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Miasta: Białystok, Bydgoszcz, Gdańsk, Gliwice i 11 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent. Randomized, multicenter, double-blind, placebo-controlled study.
Miasta: Gdańsk, Gliwice, Kielce, Opole i 1 inne miastoWiek: od 18 latSponsor: Slaskie Centrum Chorob Serca W Zabrzu
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Miasta: Białystok, Gdańsk, Katowice, Konin i 9 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel…
Miasta: Gdańsk, Kraków, Warszawa, ŁódźWiek: od 18 latSponsor: AstraZeneca AB
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases…
Miasta: Gdańsk, Kraków, Warszawa, WrocławWiek: do 64 latSponsor: Institut Gustave Roussy
RekrutujeFaza II/III
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Miasta: Gdańsk, Gliwice, Konin, Siedlce i 1 inne miastoWiek: od 0 latSponsor: Eikon Therapeutics Inc.
RekrutujeFaza II/III
Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 17.99 latSponsor: Medical University Of Lodz
RekrutujeFaza II
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian…
Miasta: Białystok, Gdańsk, Siedlce, SzczecinWiek: 18-64 latSponsor: AbbVie Deutschland GmbH & Co. KG
RekrutujeFaza III
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 9 innych miastWiek: do 64 latSponsor: Medical University Of Gdansk
RekrutujeFaza II
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated…
Miasta: Bydgoszcz, Bystra, Gdańsk, Olsztyn i 2 inne miastaWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza III
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or…
Miasta: Biała Podlaska, Białystok, Brzozów, Gdańsk i 5 innych miastWiek: od 18 latSponsor: Janssen Cilag International
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy…
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 11 innych miastWiek: do 64 latSponsor: Universita Degli Studi Di Milano Bicocca
RekrutujeFaza III
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Miasta: Gdańsk, Legnica, Olsztyn, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza I/II
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Miasta: Gdańsk, Lublin, Olsztyn, Opole i 1 inne miastoWiek: od 18 latSponsor: BeOne Medicines AG
RekrutujeFaza III
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Miasta: Gdańsk, Kielce, Kraków, Olsztyn i 4 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Miasta: Białystok, Gdańsk, Kraków, Poznań i 4 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma…
Miasta: Gdańsk, Katowice, Lublin, ŁódźWiek: od 18 latSponsor: Celgene Corp.
W Polsce: ZakończoneNa świecie: RekrutujeFaza I/II
Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer
Miasta: Gdańsk, Otwock, Poznań, WarszawaWiek: od 18 latSponsor: Fortvita Biologics (USA) Inc.
RekrutujeFaza I
Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Miasta: Gdańsk, Przemyśl, ŁódźWiek: od 18 latSponsor: Amgen Inc.
RekrutujeFaza III
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 3 inne miastaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza II
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Miasta: Biała Podlaska, Bydgoszcz, Gdańsk, Gdynia i 8 innych miastWiek: od 18 latSponsor: Ryvu Therapeutics S.A.
RekrutujeFaza III
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Miasta: Brzozów, Bydgoszcz, Gdańsk, Koszalin i 6 innych miastWiek: od 18 latSponsor: Shanghai Henlius Biotech Inc.
RekrutujeFaza III
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: Secura Bio Limited
RekrutujeFaza III
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Miasta: Białystok, Bydgoszcz, Gdańsk, Katowice i 12 innych miastWiek: od 18 latSponsor: Kartos Therapeutics Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with…
Miasta: Gdańsk, Poznań, WrocławWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Miasta: Bydgoszcz, Gdańsk, Konin, Lublin i 2 inne miastaWiek: od 18 latSponsor: OSE Immunotherapeutics